Results 1-86 of 86 (Search time: 0.006 seconds).

Issue DateTitleAuthor(s)SourcescopusWOSFulltext/Archive link
12021It takes two to tango: breakthrough advanced hepatocellular carcinoma treatment that combines anti-angiogenesis and immune checkpoint blockadeLiu T.-H.; YU-YUN SHAO ; Hsu C.-H.Journal of the Formosan Medical Association32
22021Reply to letter to the editor: Low skeletal muscle mass are predictive factors of survival for advanced hepatocellular carcinomaWu C.-H.; YU-YUN SHAO ; Ting-Fang Shih T.Journal of the Formosan Medical Association00
32021Total skeletal, psoas and rectus abdominis muscle mass as prognostic factors for patients with advanced hepatocellular carcinomaWu C.-H.; Liang P.-C.; Hsu C.-H.; Chang F.-T.; YU-YUN SHAO ; Ting-Fang Shih T.Journal of the Formosan Medical Association42
42021Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of TaiwanYU-YUN SHAO ; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy GroupJournal of the Formosan Medical Association9
52021Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinomaHung Y.-P.; YU-YUN SHAO ; Lee J.-M.; Hsu C.; Hsu C.-H.; Yang M.-H.; Chao Y.Journal of the Chinese Medical Association2
62021The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinomaHung Y.-P.; YU-YUN SHAO ; Hsu C.; Hsu C.-H.; Lee J.-M.; Yang M.-H.; Chao Y.Journal of the Formosan Medical Association0
72021Solving the deficit of cancer pain management skills by education programsYU-YUN SHAO ; Lin W.-Y.; Lin C.-P.; Lu L.-C.; Hsu C.-H.Supportive Care in Cancer1
82021An Underdiagnosed Hypothyroidism and Its Clinical Significance in Patients with Advanced Hepatocellular CarcinomaYU-YUN SHAO ; Cheng A.-L.; Hsu C.-H.Oncologist0
92021Correspondence to: Management of venous thromboembolisms: Part II. The consensus for pulmonary embolism and updatesYU-YUN SHAO ; Lin H.-J.Acta Cardiologica Sinica0
102020Solving the deficit of cancer pain management skills by education programsYU-YUN SHAO ; Lin W.-Y.; Lin C.-P.; Lu L.-C.; Hsu C.-H.Supportive Care in Cancer1
112020Satisfaction with pain management and impact of pain on quality of life in cancer patientsLin J.; Hsieh R.-K.; Chen J.-S.; Lee K.-D.; Rau K.-M.; YU-YUN SHAO ; Sung Y.-C.; Yeh S.-P.; Chang C.-S.; Liu T.-C.; Wu M.-F.; Lee M.-Y.; Yu M.-S.; Yen C.-J.; Lai P.-Y.; Hwang W.-L.; Chiou T.-J.Asia-Pacific Journal of Clinical Oncology30
122020A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib MonotherapyLin Z.-Z.; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; YU-YUN SHAO ; Hsu C.-H.; Cheng A.-L.; Lee R.-C.; Chao Y.; Hsu C.Oncologist12
132020The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinomaHung Y.-P.; YU-YUN SHAO ; Hsu C.; Hsu C.-H.; Lee J.-M.; Yang M.-H.; Chao Y.Journal of the Formosan Medical Association0
142020Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of TaiwanYU-YUN SHAO ; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy GroupJournal of the Formosan Medical Association39
152019Potent activity of composite cyclin dependent kinase inhibition against hepatocellular carcinomaYU-YUN SHAO ; Li Y.-S.; Hsu H.-W.; Lin H.; Wang H.-Y.; Wo R.R.; Cheng A.-L.; Hsu C.-H.Cancers06
162019Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinomaYU-YUN SHAO ; Liu T.-H.; Hsu C.; Lu L.-C.; Shen Y.-C.; Lin Z.-Z.; Cheng A.-L.; Hsu C.-H.Liver International815
172019Understanding transdermal buprenorphine and a practical guide to its use for chronic cancer and non-cancer pain managementO'Brien T.; Ahn J.S.; Chye R.; Le B.; Lu H.; Olarte G.; Palladini M.; Salti A.; YU-YUN SHAO ; Yaakup H.; Buemio K.C.; Colin C.G.; Hadjiat Y.Journal of Opioid Management10
182019Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib TreatmentLu L.-C.; Lee Y.-H.; Chang C.-J.; Shun C.-T.; Fang C.-Y.; YU-YUN SHAO ; Liu T.-H.; Cheng A.-L.; Hsu C.-H.Liver Cancer1029
192019Patients with head and neck cancer may need more intensive pain management to maintain daily functioning: a multi-center studyCho S.-F.; Rau K.-M.; YU-YUN SHAO ; Yen C.-J.; Wu M.-F.; Chen J.-S.; Chang C.-S.; Yeh S.-P.; Chiou T.-J.; Hsieh R.-K.; Lee M.-Y.; Sung Y.-C.; Lee K.-D.; Lai P.-Y.; Yu M.-S.; Hwang W.-L.; Liu T.-C.Supportive Care in Cancer55
202019Neutrophil-to-lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint InhibitorsGuo J.-C.; Lin C.-C.; Lin C.-Y.; Hsieh M.-S.; Kuo H.-Y.; Lien M.-Y.; YU-YUN SHAO ; Huang T.-C.; Hsu C.-H.Anticancer research1113
212019A nationwide survey of adherence to analgesic drugs among cancer patients in Taiwan: prevalence, determinants, and impact on quality of lifeChou W.-C.; Chen J.-S.; Hung C.-Y.; Lu C.-H.; YU-YUN SHAO ; Chiou T.-J.; Sung Y.-C.; Rau K.-M.; Yen C.-J.; Yeh S.-P.; Liu T.-C.; Wu M.-F.; Lee M.-Y.; Yu M.-S.; Hwang W.-L.; Lai P.-Y.; Chang C.-S.; Hsieh R.-K.Supportive Care in Cancer66
222019Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular CarcinomaLu L.-C.; Hsu C.; YU-YUN SHAO ; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; Liu T.-H.; Hsu C.-H.; Cheng A.-L.Liver Cancer226
232019Considerations of heterogeneity in clinical trials for hepatocellular carcinomaLiu T.-H.; YU-YUN SHAO ; Lu L.-C.; Shen Y.-C.; Hsu C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L.Expert Review of Gastroenterology and Hepatology15
242018Successful Hepatic Arterial Infusion of Chemotherapy in a Patient with Advanced Hepatocellular Carcinoma and Impending Liver FailureLiu T.-H.; Hsu C.-H.; YU-YUN SHAO Liver Cancer11
252018Development of a general method for quantifying IgG-based therapeutic monoclonal antibodies in human plasma using protein G purification coupled with a two internal standard calibration strategy using LC-MS/MSChiu H.-H.; Liao H.-W.; YU-YUN SHAO ; Lu Y.-S.; Lin C.-H.; Tsai I.-L.; Kuo C.-H.Analytica Chimica Acta2227
262018A Phase i study of S-1-based concurrent chemoradiotherapy followed by gemcitabine and S-1 in metastatic pancreatic adenocarcinomaYang S.-H.; YU-YUN SHAO ; Lin C.-C.; Kuo S.-H.; Cheng A.-L.; Yeh K.-H.Anticancer Research21
272017Do-not-resuscitate consent signed by patients indicates a more favorable quality of end-of-life care for patients with advanced cancerLiang Y.-H.; Wei C.-H.; Hsu W.-H.; YU-YUN SHAO ; Lin Y.-C.; Chou P.-C.; Cheng A.-L.; Yeh K.-H.Supportive Care in Cancer67
282017Irinotecan and oxaliplatin might provide equal benefit as adjuvant chemotherapy for patients with resectable synchronous colon cancer and liver-confined metastases: A nationwide database studyLiang Y.-H.; YU-YUN SHAO ; Chen H.-M.; Cheng A.-L.; Lai M.-S.; Yeh K.-H.Anticancer Research57
292017Right or left? Side selection for a totally implantable vascular access device: A randomised observational studyLin W.-Y.; Lin C.-P.; Hsu C.-H.; Lee Y.-H.; Lin Y.-T.; Hsu M.-C.; YU-YUN SHAO British Journal of Cancer76
302017Prescription patterns of sorafenib and outcomes of patients with advanced hepatocellular carcinoma: A national population studyLu L.-C.; Chen P.-J.; Yeh Y.-C.; Hsu C.-H.; Chen H.-M.; Lai M.-S.; YU-YUN SHAO ; Cheng A.-L.Anticancer Research1213
312017Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacyYU-YUN SHAO ; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C.Alimentary Pharmacology and Therapeutics66
322017Hepatitis C virus core protein potentiates proangiogenic activity of hepatocellular carcinoma cellsYU-YUN SHAO ; Hsieh M.-S.; Wang H.-Y.; Li Y.-S.; Lin H.; Hsu H.-W.; Huang C.-Y.; Hsu C.-H.; Cheng A.-L.Oncotarget47
332017High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinomaYU-YUN SHAO ; Lin H.; Li Y.-S.; Lee Y.-H.; Chen H.-M.; Cheng A.-L.; Hsu C.-H.Japanese Journal of Clinical Oncology2323
342017Impact of Undertreatment of Cancer Pain With Analgesic Drugs on Patient Outcomes: A Nationwide Survey of Outpatient Cancer Patient Care in TaiwanShen W.-C.; Chen J.-S.; YU-YUN SHAO ; Lee K.-D.; Chiou T.-J.; Sung Y.-C.; Rau K.-M.; Yen C.-J.; Liao Y.-M.; Liu T.-C.; Wu M.-F.; Lee M.-Y.; Yu M.-S.; Hwang W.-L.; Lai P.-Y.; Chang C.-S.; Chou W.-C.; Hsieh R.-K.Journal of Pain and Symptom Management76
352017Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)Abou-Alfa G.K.; Yen C.-J.; Hsu C.-H.; O’Donoghue J.; Beylergil V.; Ruan S.; Pandit-Taskar N.; Gansukh B.; Lyashchenko S.K.; Ma J.; Wan P.; YU-YUN SHAO ; Lin Z.-Z.; Frenette C.; O’Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Ohishi N.; Chen Y.-C.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; Cheng A.-L.; Carrasquilo J.A.Cancer Chemotherapy and Pharmacology1414
362017National policies fostering hospice care increased hospice utilization and reduced the invasiveness of end-of-life care for cancer patientsYU-YUN SHAO ; Hsiue E.H.-C.; Hsu C.-H.; Yao C.-A.; Chen H.-M.; Lai M.-S.; Cheng A.-L.Oncologist108
372016Key opioid prescription concerns in cancer patients: A nationwide studyLin C.-P.; Hsu C.-H.; Fu W.-M.; Chen H.-M.; Lee Y.-H.; Lai M.-S.; YU-YUN SHAO Acta Anaesthesiologica Taiwanica70
382016Influence of age on opioid prescription of patients with advanced lung cancerLee H.-S.; Lin C.-P.; Chen H.-M.; YU-YUN SHAO Annals of Oncology00
392016Modified CLIP with objective liver reserve assessment retains prognosis prediction for patients with advanced hepatocellular carcinomaYU-YUN SHAO ; Liu T.-H.; Lee Y.-H.; Hsu C.-H.; Cheng A.-L.Journal of Gastroenterology and Hepatology (Australia)1620
402016Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: A nationwide cohort studyChen K.-H.; YU-YUN SHAO ; Chen H.-M.; Lin Y.-L.; Lin Z.-Z.; Lai M.-S.; Cheng A.-L.; Yeh K.-H.BMC Cancer3132
412016Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinomaLin H.-H.; Feng W.-C.; Lu L.-C.; YU-YUN SHAO ; Hsu C.-H.; Cheng A.-L.Cancer Letters2532
422016Cytotoxic chemotherapy as first-line therapy for advanced non-small-cell lung cancer in Taiwan: Daily practiceLiang Y.-H.; YU-YUN SHAO ; Liao B.-C.; Lee H.-S.; Yang J.C.-H.; Chen H.-M.; Chiang C.-J.; Cheng A.-L.; Lai M.-S.Journal of Cancer46
432016Cyclin E1 inhibition can overcome sorafenib resistance in hepatocellular carcinoma cells through Mcl-1 suppressionHsu C.; Lin L.-I.; Cheng Y.-C.; Feng Z.-R.; YU-YUN SHAO ; Cheng A.-L.; Ou D.-L.Clinical Cancer Research2428
442016Lenalidomide as second-line therapy for advanced hepatocellular carcinoma (HCC): biomarker explorationYU-YUN SHAO ; Chen B.-B.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C.Annals of Oncology01
452015High serum transforming growth factor-β1 levels predict outcome in hepatocellular carcinoma patients treated with sorafenibLin T.-H.; YU-YUN SHAO ; Chan S.-Y.; Huang C.-Y.; Hsu C.-H.; Cheng A.-L.Clinical Cancer Research5062
462015Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinomaLiao B.-C.; YU-YUN SHAO ; Chen H.-M.; Shau W.-Y.; Lin Z.-Z.; Kuo R.N.; Lai C.-L.; Chen K.-H.; Cheng A.-L.; Yang J.C.-H.; Lai M.-S.Clinical Lung Cancer88
472015Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: A meta-analysis of randomized clinical trialsYU-YUN SHAO ; Shau W.-Y.; Chan S.-Y.; Lu L.-C.; Hsu C.-H.; Cheng A.-L.Oncology (Switzerland)2423
482015Statin Use Is Associated With Improved Prognosis of Colorectal Cancer in TaiwanYU-YUN SHAO ; Hsu C.-H.; Yeh K.-H.; Chen H.-M.; Yeh Y.-C.; Lai C.-L.; Lin Z.-Z.; Cheng A.-L.; Lai M.-S.Clinical Colorectal Cancer2525
492015Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there?YU-YUN SHAO ; Hsu C.-H.; Cheng A.-L.World Journal of Gastroenterology2629
502015The prognostic impact of type 2 diabetes mellitus on early cervical cancer in AsiaKuo H.-Y.; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; YU-YUN SHAO ; Hsu C.; Cheng W.-F.; Cheng A.-L.; Yang J.C.H.; Lai M.-S.Oncologist89
512015Young patients with colorectal cancer have increased risk of second primary cancersLiang Y.-H.; YU-YUN SHAO ; Chen H.-M.; Lai C.-L.; Lin Z.-Z.; Kuo R.N.; Cheng A.-L.; Yeh K.-H.; Lai M.-S.Japanese Journal of Clinical Oncology67
522015Integrated stable isotope labeling by amino acids in cell culture (SILAC) and isobaric tags for relative and absolute quantitation (iTRAQ) quantitative proteomic analysis identifies galectin-1 as a potential biomarker for predicting sorafenib resistance in liver cancerYeh C.-C.; Hsu C.-H.; YU-YUN SHAO ; Ho W.-C.; Tsai M.-H.; Feng W.-C.; Chow L.-P.Molecular and Cellular Proteomics3443
532014Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapyYU-YUN SHAO ; Wu C.-H.; Lu L.-C.; Chan S.-Y.; Ma Y.-Y.; Yen F.-C.; Hsu C.-H.; Cheng A.-L.Journal of Hepatology3640
542014Type 2 diabetes mellitus is associated with increased mortality in chinese patients receiving curative surgery for colon cancerChen K.-H.; YU-YUN SHAO ; Lin Z.-Z.; Yeh Y.-C.; Wen-Yi S.; Kuo R.N.; Chen H.-M.; Lai C.-L.; Yeh K.-H.; Cheng A.-L.; Lai M.-S.Oncologist1717
552014Clinical activity of metronomic chemotherapy in liver cancersYU-YUN SHAO ; Cheng A.-L.; Hsu C.-H.Metronomic Chemotherapy: Pharmacology and Clinical Applications00
562014β-Catenin (CTNNB1) mutations are not associated with prognosis in advanced hepatocellular carcinomaLu L.-C.; YU-YUN SHAO ; Lee Y.-H.; Hsieh M.-S.; Hsiao C.-H.; Lin H.-H.; Kao H.-F.; Ma Y.-Y.; Yen F.-C.; Cheng A.-L.; Hsu C.-H.Oncology (Switzerland)1114
572014Long-term disease-free survival achieved by anti-angiogenic therapy plus surgery in a hepatocellular carcinoma patient with extensive liver involvement and lung metastasesYU-YUN SHAO ; Ho M.-C.; Cheng A.-L.; Hsu C.-H.Journal of the Formosan Medical Association23
582014Clinical characteristics of advanced hepatocellular carcinoma patients with prolonged survival in the era of anti-angiogenic targeted-therapyLu L.-C.; YU-YUN SHAO ; Chan S.-Y.; Hsu C.-H.; Cheng A.-L.Anticancer Research78
592013Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinomaLu L.-C.; YU-YUN SHAO ; Kuo R.N.C.; Lin Z.-Z.; Yeh Y.-C.; Shau W.-Y.; Hsu C.-H.; Cheng A.-L.; Lai M.-S.Cancer98
602013The germline BIM deletion polymorphism is not associated with the treatment efficacy of sorafenib in patients with advanced hepatocellular carcinomaYU-YUN SHAO ; Chang Y.-L.; Huang C.-Y.; Hsu C.-H.; Cheng A.-L.Oncology (Switzerland)55
612013Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor sizeLin Z.-Z.; Shau W.-Y.; Hsu C.; YU-YUN SHAO ; Yeh Y.-C.; Kuo R.N.-C.; Hsu C.-H.; Yang J.C.-H.; Cheng A.-L.; Lai M.-S.PLoS ONE2322
622013A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapyYU-YUN SHAO ; Liang P.-C.; Wu Y.-M.; Huang C.-C.; Huang K.-W.; Cheng J.C.; Hsu C.-H.; Hsu C.; Cheng A.-L.; Lin Z.-Z.Liver International1213
632013Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancerYU-YUN SHAO ; Shau W.-Y.; Lin Z.-Z.; Chen H.-M.; Kuo R.; Yang J.C.-H.; Lai M.-S.European Journal of Cancer2018
642013Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II studyHsu C.-H.; Kang Y.K.; Yang T.-S.; Shun C.-T.; YU-YUN SHAO ; Su W.-C.; Sandoval-Tan J.; Chiou T.-J.; Jin K.; Hsu C.; Cheng A.-L.Oncology (Switzerland)3639
652012Dissimilar immunohistochemical expression of ERK and AKT between paired biopsy and hepatectomy tissues of hepatocellular carcinomaYU-YUN SHAO ; Chen C.-L.; Ho M.-C.; Huang C.-C.; Tu H.-C.; Hsu C.-H.; Cheng A.-L.Anticancer Research810
662012Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinomaShau W.-Y.; YU-YUN SHAO ; Yeh Y.-C.; Lin Z.-Z.; Kuo R.; Hsu C.-H.; Hsu C.; Cheng A.-L.; Lai M.-S.Oncologist2828
672012Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinomaYU-YUN SHAO ; Lin Z.-Z.; Hsu C.; Lee K.-D.; Hsiao C.-H.; Lu Y.-S.; Huang C.-C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.Oncology2625
682012Survival following surgery with or without adjuvant chemotherapy for stage I-IIIA non-small cell lung cancer: An East Asian population-based studyLin Z.-Z.; Shau W.-Y.; YU-YUN SHAO ; Yang Y.-Y.; Kuo R.N.-C.; Yang J.C.-H.; Laie M.-S.Oncologist56
692012Survival of patients with small cell lung carcinoma in TaiwanKuo Y.-H.; Lin Z.-Z.; Yang Y.-Y.; YU-YUN SHAO ; Shau W.-Y.; Kuo R.N.C.; Yang J.C.-H.; Lai M.-S.Oncology1815
702012Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapyLin Z.-Z.; Hsu C.; Hu F.-C.; YU-YUN SHAO ; Chang D.-Y.; Yang C.-H.; Hong R.-L.; Hsu C.-H.; Chengb A.-L.Oncologist810
712012Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancerLu L.-C.; YU-YUN SHAO ; Hsu C.-H.; Hsu C.; Cheng W.-F.; Lin Y.-L.; Cheng A.-L.; Yeh K.-H.Anticancer Research2832
722012The impact of diabetes mellitus on prognosis of early breast cancer in AsiaChen W.-W.; YU-YUN SHAO ; Shau W.-Y.; Lin Z.-Z.; Lu Y.-S.; Chen H.-M.; Kuo R.N.C.; Cheng A.-L.; Lai M.-S.Oncologist3634
732012Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systemsYU-YUN SHAO ; Lu L.-C.; Lin Z.-Z.; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.British Journal of Cancer2324
742012Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapyYU-YUN SHAO ; Huang C.-C.; Lin S.-D.; Hsu C.-H.; Cheng A.-L.Clinical Cancer Research3433
752011Impact of baseline hepatitis B viral DNA levels on survival of patients with advanced hepatocellular carcinomaYU-YUN SHAO ; Chen P.-J.; Lin Z.-Z.; Huang C.-C.; Ding Y.-H.; Lee Y.-H.; Hsu C.-H.; Cheng A.-L.Anticancer Research8
762011High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapyYU-YUN SHAO ; Lin Z.-Z.; Chen T.-J.; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.Oncology1615
772011Increasing incidence of brain metastasis in patients with advanced Hepatocellular carcinoma in the era of Antiangiogenic targeted therapyYU-YUN SHAO ; Lu L.-C.; Cheng A.-L.; Hsu C.-H.Oncologist2825
782010Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinomaHsu C.-H.; Shen Y.-C.; Lin Z.-Z.; Chen P.-J.; YU-YUN SHAO ; Ding Y.-H.; Hsu C.; Cheng A.-L.Journal of Hepatology109100
792010Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinomaYU-YUN SHAO ; Huang C.; Liang P.; Lin Z.-Z.Asia-Pacific Journal of Clinical Oncology2625
802010Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatinYU-YUN SHAO ; Kuo K.-T.; Hu F.-C.; Lu Y.-S.; Huang C.-S.; Liau J.-Y.; Lee W.-C.; Hsu C.; Kuo W.-H.; Chang K.-J.; Lin C.-H.; Cheng A.-L.Japanese Journal of Clinical Oncology2220
812010Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinomaYU-YUN SHAO ; Lin Z.-Z.; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.Cancer125130
822010Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer.YU-YUN SHAO ; Lin C.C.; Yang C.H.Discovery medicine1312
832010Characteristics and risk factors of oxaliplatin-related hypersensitivity reactionsYU-YUN SHAO ; Hu F.-C.; Liang J.-T.; Chiu W.-T.; Cheng A.-L.; Yang C.-H.Journal of the Formosan Medical Association2521
842010Pleural metastases as a unique entity with dismal outcome of head and neck squamous cell carcinomaYU-YUN SHAO ; Hong R.-L.Oral Oncology44
852009Gastric perforation presenting as empyema in a patient with pancreatic cancer on bevacizumab treatmentYU-YUN SHAO ; Lin Z.-Z.; Liang P.-C.; Tien Y.-W.; Cheng A.-L.Anticancer Research11
862008Fatal thrombocytopenia after oxaliplatin-based chemotherapyYU-YUN SHAO ; Hong R.-L.Anticancer Research1619